Atossa Therapeutics, Inc. 2020 Form 10-K Summary
Business Context and Reporting Period
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, breast conditions and COVID-19. Its principal programs are oral Endoxifen for breast cancer and mammographic breast density, AT-301 nasal spray for at-home COVID-19 treatment or prevention, and AT-H201 inhalation therapy for hospitalized COVID-19 patients. The fiscal year ended December 31, 2020. The company had no products approved for commercialization and generated no sustainable revenue.
Key Financial Metrics
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $6.6 million | $6.6 million | Down approximately 1% |
| General and administrative expense | $8.0 million | $10.6 million | Down approximately 25% |
| Total operating expenses | $14.6 million | $17.3 million | Down approximately 15% |
| Net loss | $17.8 million | $17.2 million | Loss increased approximately 3% |
| Net loss attributable to common shareholders | $22.3 million | $17.2 million | Impacted by $4.5 million deemed preferred-stock dividend |
| Basic and diluted loss per share | $1.97 loss | $2.03 loss | Per-share loss decreased |
| Cash and cash equivalents | $39.6 million | $12.6 million | Increased materially |
| Working capital | $27.1 million | Not clearly provided | Not comparable from disclosed text |
| Total liabilities | $15.7 million | $1.3 million | Increased primarily from warrant liability |
| Stockholders’ equity | $27.2 million | $13.2 million | Increased approximately $14.0 million |
Net cash used in operating activities was $11.6 million in the consolidated statements of cash flows, compared with $9.1 million in 2019. The MD&A section separately cites approximately $12.5 million of operating cash use; the filing does not explain this discrepancy. Investing cash use was negligible at approximately $9,000. Financing activities provided $38.6 million, primarily from ATM sales and December equity, preferred-stock and warrant offerings.
The company had no conventional debt disclosed. Its principal financing-related obligation was a $13.0 million liability for warrants issued in December 2020. Restricted cash was $110,000. Cash deposits exceeding FDIC insurance limits totaled approximately $39.3 million at year-end.
Material Changes Versus the Prior Comparable Period
- Operating expenses declined $2.7 million, primarily because stock-based compensation decreased in both R&D and G&A.
- R&D spending was broadly stable, while G&A spending decreased due mainly to lower non-cash compensation, partly offset by higher legal, professional and insurance costs.
- Net loss increased modestly because the company recorded $2.3 million of warrant fair-value expense and $0.9 million of warrant financing expense.
- December financings generated approximately $34.0 million of net proceeds from common-stock, preferred-stock and warrant transactions; the company also raised approximately $4.7 million through its Oppenheimer ATM.
- Common shares outstanding increased from approximately 9.1 million at December 31, 2019 to 47.5 million at December 31, 2020, before additional 2021 issuances and warrant exercises.
- The company recorded a $4.5 million deemed dividend associated with Series C convertible preferred stock, reducing net loss attributable to common shareholders.
Programs, Outlook, Risks and Unusual Items
- Endoxifen: A Phase 2 Australian window-of-opportunity study enrolled seven patients and was discontinued in February 2021 after preliminary results from six patients showed an approximately 74% reduction in Ki-67 tumor-cell proliferation. Management plans to seek FDA guidance for a U.S. study, but biomarker reduction may not be an approvable endpoint.
- Endoxifen for mammographic breast density: A Phase 2 oral study in Sweden remained subject to regulatory and ethics approvals and COVID-19-related enrollment restrictions. The prior topical program showed reductions in breast density but substantial skin irritation, and the company does not plan to continue developing the topical formulation.
- AT-301: A 32-subject Phase 1 study reported no serious adverse events, discontinuations or bronchospasms. The company planned additional preclinical work before seeking authorization for a U.S. Phase 2 study.
- AT-H201: In vitro testing showed activity against SARS-CoV-2, but the FDA requested additional preclinical and other information. The initial Australian clinical study remained subject to regulatory authorization.
- Management expected R&D expense to increase in 2021 as clinical and preclinical programs advanced. The company did not provide revenue, earnings or product-launch guidance.
- The company expected available resources, including approximately $102.4 million raised from January through March 24, 2021, to fund planned operations into 2024, depending on clinical-trial timing and spending. It nevertheless expects continuing operating losses and may require additional capital.
- COVID-19 could delay regulatory reviews, patient enrollment, clinical sites, supply chains and access to capital. The company reported no drug-supply delays through the filing date.
- Management identified a material weakness in internal control over financial reporting related to accounting for complex financing transactions and warrant classification. The classification error was corrected before the financial statements were issued, but remediation had not yet been completed and tested.
- Warrants issued in December 2020 were classified as liabilities because certain provisions could require cash settlement. The company expected adoption of ASU 2020-06 on January 1, 2021 to reclassify the $13.0 million warrant liability to equity through a beginning-equity adjustment.
- The company relies extensively on third-party manufacturers, suppliers, clinical research organizations and medical institutions. Regulatory approval, clinical efficacy, safety, manufacturing, intellectual-property protection and commercialization remain uncertain.
Important Facts for Investors to Verify
- Reconcile the filing’s inconsistent disclosures regarding 2020 operating cash flow of approximately $11.6 million versus $12.5 million.
- Review the terms, potential dilution and accounting treatment of outstanding warrants, including the $13.0 million liability warrants and subsequent 2021 warrant exercises.
- Assess post-year-end financing proceeds, share issuances and the resulting dilution to holders of common stock.
- Monitor whether the material weakness in internal control over financial reporting has been remediated and independently tested.
- Verify regulatory status, FDA feedback and planned clinical-trial milestones for Endoxifen, AT-301 and AT-H201.
- Evaluate cash burn relative to management’s projected funding horizon, recognizing that the company has no approved products or recurring revenue.
- Review the reliability and maturity of preliminary clinical data, particularly the small six-patient Endoxifen dataset and the 32-subject AT-301 safety study.